Previous close | 135.64 |
Open | 136.02 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1100 |
Day's range | 135.35 - 137.15 |
52-week range | 119.59 - 145.58 |
Volume | |
Avg. volume | 989,818 |
Market cap | 15.213B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | 18.41 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.00 (2.19%) |
Ex-dividend date | 05 Apr 2024 |
1y target est | N/A |
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time.
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.